Australian government funds dementia research fellows

19 October 2015
australia-big

The Australian government has committed A$40 million ($29 million) to 76 early career researchers working to find a cure and therapies for dementia.

This comes as part of the Australian government’s A$200 million commitment to boosting dementia research in the country. It follows the announcement in August of the establishment of the Dementia Institute and A$35.6 million for research team grants as its first initiative.

John McCallum, the director of the NHMRC National Institute for Dementia Research, said: “Dementia is the most feared and biggest health issue facing the developed world. If we want to boost research to deal with this, we must invest in new researchers to build the future research workforce. We already know that more than 340,000 Australians are living with dementia, and without a medical breakthrough the number of people with dementia is expected to be almost 900,000 by 2050. This is why boosting dementia research is so critical. Through the collaboration of Australia’s world leading researchers with new Fellows, we can make a difference to finding a cure for this debilitating disease, which has now become Australia’s second leading cause of death.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical